Last reviewed · How we verify

IPV at 6 and fIPV at 22 weeks, Rotarix

Centers for Disease Control and Prevention · FDA-approved active Biologic

IPV at 6 and fIPV at 22 weeks, Rotarix is a vaccine Biologic drug developed by Centers for Disease Control and Prevention. It is currently FDA-approved for Prevention of poliomyelitis (poliovirus types 1, 2, and 3), Prevention of rotavirus gastroenteritis.

IPV (inactivated poliovirus vaccine) and fIPV (fractional dose IPV) stimulate immune responses against poliovirus types 1, 2, and 3, while Rotarix protects against rotavirus infection through live attenuated viral immunization.

IPV (inactivated poliovirus vaccine) and fIPV (fractional dose IPV) stimulate immune responses against poliovirus types 1, 2, and 3, while Rotarix protects against rotavirus infection through live attenuated viral immunization. Used for Prevention of poliomyelitis (poliovirus types 1, 2, and 3), Prevention of rotavirus gastroenteritis.

At a glance

Generic nameIPV at 6 and fIPV at 22 weeks, Rotarix
SponsorCenters for Disease Control and Prevention
Drug classvaccine
ModalityBiologic
Therapeutic areaImmunology
PhaseFDA-approved

Mechanism of action

IPV contains chemically inactivated poliovirus that triggers humoral and cellular immunity without causing disease. Rotarix is a live attenuated rotavirus vaccine that replicates in the intestinal tract, inducing mucosal and systemic immune responses. Together, these vaccines prevent poliomyelitis and rotavirus gastroenteritis through antibody production and T-cell mediated immunity.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about IPV at 6 and fIPV at 22 weeks, Rotarix

What is IPV at 6 and fIPV at 22 weeks, Rotarix?

IPV at 6 and fIPV at 22 weeks, Rotarix is a vaccine drug developed by Centers for Disease Control and Prevention, indicated for Prevention of poliomyelitis (poliovirus types 1, 2, and 3), Prevention of rotavirus gastroenteritis.

How does IPV at 6 and fIPV at 22 weeks, Rotarix work?

IPV (inactivated poliovirus vaccine) and fIPV (fractional dose IPV) stimulate immune responses against poliovirus types 1, 2, and 3, while Rotarix protects against rotavirus infection through live attenuated viral immunization.

What is IPV at 6 and fIPV at 22 weeks, Rotarix used for?

IPV at 6 and fIPV at 22 weeks, Rotarix is indicated for Prevention of poliomyelitis (poliovirus types 1, 2, and 3), Prevention of rotavirus gastroenteritis.

Who makes IPV at 6 and fIPV at 22 weeks, Rotarix?

IPV at 6 and fIPV at 22 weeks, Rotarix is developed and marketed by Centers for Disease Control and Prevention (see full Centers for Disease Control and Prevention pipeline at /company/centers-for-disease-control-and-prevention).

What drug class is IPV at 6 and fIPV at 22 weeks, Rotarix in?

IPV at 6 and fIPV at 22 weeks, Rotarix belongs to the vaccine class. See all vaccine drugs at /class/vaccine.

What development phase is IPV at 6 and fIPV at 22 weeks, Rotarix in?

IPV at 6 and fIPV at 22 weeks, Rotarix is FDA-approved (marketed).

What are the side effects of IPV at 6 and fIPV at 22 weeks, Rotarix?

Common side effects of IPV at 6 and fIPV at 22 weeks, Rotarix include Local injection site reactions (pain, redness, swelling), Fever, Irritability or fussiness, Diarrhea (Rotarix), Vomiting (Rotarix).

Related